While there are currently no therapeutic options for Ebola, preliminary data from a...
ViiV’s long-acting HIV regimen passes late-stage trial
ViiV Healthcare has reported that the Phase III ATLAS-2M clinical trial of its long-acting, two-drug regimen developed to treat HIV infection met its primary endpoint.
New, efficacious options offer hope for Ebola treatment and containment
While there are currently no therapeutic options for Ebola, preliminary data from a clinical trial in the DRC that compared four drugs for the treatment of Ebola showed promising results.
Two monoclonal antibodies show promise in PALM Ebola trial
Preliminary findings from the Pamoja Tulinde Maisha (PALM) clinical trial have revealed that two monoclonal antibodies, REGN-EB3 and mAb114, produced a higher chance of survival in Ebola patients.
Cidara reports positive data from Phase II trial of rezafungin
Cidara Therapeutics has announced that its antifungal candidate rezafungin met all efficacy, safety, and tolerability measures in part B of Phase II STRIVE (STRIVE B) clinical trial involving candidemia and/or invasive candidiasis patients.
ViiV reports new data from Dovato’s GEMINI 1 and 2 trials
ViiV Healthcare has reported new positive results from the Phase III GEMINI 1 and 2 clinical trials evaluating Dovato, a two-drug regimen of dolutegravir and lamivudine, to treat HIV-1 infection.
Merck reports positive data from islatravir’s HIV trial
Merck has reported positive findings from a Phase I clinical trial conducted in healthy volunteers to study extended administration of its HIV drug islatravir using a sub-dermal drug-eluting implant.
Dovato (dolutegravir/lamivudine) for the Treatment of HIV Infection
Dovato® (dolutegravir/lamivudine) is a two-drug regimen indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults.
Delstrigo for the Treatment of HIV-1 Infection
Delstrigo™ is a fixed-dose combination tablet of antiretroviral drugs doravirine, lamivudine, and tenofovir disoproxil fumarate indicated for the treatment of human immunodeficiency virus (HIV) 1 infection.
Revcovi for the Treatment of ADA-SCID
Revcovi (elapegademase-lvlr) is a PEGylated recombinant adenosine deaminase (rADA) enzyme indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in paediatric and adult patients.
ViiV Healthcare unveils Phase III trial results of monthly shots to combat HIV
The results investigated the efficacy and safety of cabotegravir/rilpivirine, the company’s once-monthly injection for treating HIV.